Bioengineered ncRNAs selectively change cellular miRNome profiles for cancer therapy

Data Supplement

• Supplemental Data -

  Supplemental Figure 1. Independence on Sephadex aptamer for heterogeneous expression of ncRNAs in E. coli
  

  Supplemental Figure 2. Map of nCAR-based plasmid for the production of BERAs. nCAR was placed into the pBSTNAV vector, driven under lpp promoter and selected via ampicillin resistance (AmpR)
  

  Supplemental Figure 3. HPLC determination of the purity of isolated BERAs
  

  Supplemental Figure 4. qPCR verification of the degree of changes in target miRNAs and some mRNAs identified by RNA sequencing study
  

  Supplemental Figure 5. Impact of Dicer status on the control of protein levels of target genes by bioengineered miR-34a and miR-124
  

  Supplemental Figure 6. (A) Mouse body weights showed a steady increase during the treatments and did not differ between treatment groups (P > 0.05; two-way ANOVA), suggesting that BERA therapeutics were well tolerated in mice
  

  Supplemental Figure 7. Bioengineered RNAs have minor effects on cytokine release in immunocompetent BALB/c mice, as indicated by minimal changes of serum IL-6 (A) and TNFα (B) levels
  

  Supplemental Table 1. List of siRNA and RNA aptamer sequences obtained from literature for bioengineering of target ncRNA agents
  

  Supplemental Table 2. Sequences of target BERAs and primers used for the construction of corresponding plasmids
  

  Supplemental Table 3. Yields and purities of nCAR/miR-34a-5p and nCAR/miR-124-3p isolated by single- and double-column-based, small-scale purification methods
  

  Supplemental Table 4. Primers used for RT-qPCR analyses of miRNAs and mRNAs in this study
  

  References